Navigation Links
DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
Date:3/3/2008

ANN ARBOR, Mich., March 3 /PRNewswire/ -- Terumo Heart, Inc. announced today that they have received conditional approval from the Food and Drug Administration (FDA) to begin enrollment in the US Pivotal Trial of the DuraHeart (TM) LVAS for a Bridge-to-Transplant (BTT) indication.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070227/CLTU043LOGO )

(Photo: http://www.newscom.com/cgi-bin/prnh/20080303/CLM012 )

Dr. David Munjal, Vice President of Clinical Studies, Regulatory Affairs and Quality Systems at Terumo Heart, Inc., commented: "We are extremely pleased that FDA has allowed us to move directly to the Pivotal Trial based on our existing European data. The conditional approval was granted pending answers to some additional questions. Terumo Heart, Inc. has already responded to the FDA concerning these questions and final approval is anticipated in the near future."

Dr. Chisato Nojiri, M.D., Ph.D., Chief Executive Officer for Terumo Heart, Inc., said: "The approval of the IDE Pivotal Trial is a major milestone for Terumo Heart and we are especially pleased that the FDA has also issued approval for patients to be discharged home. This positive decision by the FDA was based on our robust preclinical data and the successful European clinical trial of the DuraHeart System."

The Pivotal Trial will be a multi-center, prospective, non-randomized study of 140 patients and will include up to 40 centers. The Principal Investigators will be Francis Pagani, M.D., Ph.D., from the University of Michigan and Yoshifumi Naka, M.D., Ph.D., from Columbia Presbyterian Hospital in New York.

The DuraHeart LVAS is a third generation circulatory support device intended to provide cardiac support for patients who are at risk of death due to end-stage left ventricular failure. It i
'/>"/>

SOURCE Terumo Heart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
2. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
3. Vermillion Receives Award From the Society of Gynecologic Oncologists
4. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
5. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
6. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
11. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Suisse, October 1, 2014 ... dans le domaine de l,analyse des données issues ... une solution de diagnostic in vitro (IVD) du ... complète de la mucoviscidose dans un seul essai ... caractériser tous les types de variantes par l,intermédiaire ...
(Date:9/30/2014)...  Hologic, Inc. (NASDAQ: HOLX ), today ... Chief Executive Officer, will preside over the NASDAQ Stock ... day of Breast Cancer Awareness Month. In his remarks, ... the important benefits of Hologic,s 3D Mammography technology, the ... superior to traditional mammography. This is the ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Arbor Pharmaceuticals, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
Breaking Medicine Technology:Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3
... Fla., March 14, 2011 American Scientific Resources, ... "Company") announces that British-based Syner-Med (Pharmaceutical Products) Ltd. ... United Kingdom and Republic of Ireland for its ... 5,000 non-contact thermometers, comprised of both retail and ...
... Transgenomic, Inc. (OTC Bulletin Board: TBIO ... with the Dana-Farber Cancer Institute, Boston, MA, for the ... Transgenomic had licensed exclusive rights to COLD-PCR for Sanger ... the technology covered to include Ice COLD-PCR, a technique ...
Cached Medicine Technology:American Scientific Resources Announces New Distributor Syner-Med Placing Kidz-Med VeraTemp in the United Kingdom and Ireland 2American Scientific Resources Announces New Distributor Syner-Med Placing Kidz-Med VeraTemp in the United Kingdom and Ireland 3Transgenomic Expands COLD-PCR License 2Transgenomic Expands COLD-PCR License 3Transgenomic Expands COLD-PCR License 4
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog ... prices for smokers. , Smoking will always have a ... is the best method to find affordable coverage. Insurance ... need coverage. , Whole life insurance premiums will ... Since the coverage is permanent, the initial rates ...
(Date:10/1/2014)... Conn. (PRWEB) October 01, 2014 ... company, including a redefined mission and visual identity ... power of partnering with them to create greater ... agile brand that focuses on empowering customers to ... communications. , The crown jewel of the rebrand ...
(Date:10/1/2014)... Between 23 million and 50 million people ... figures from the National Institutes of Health (NIH) and ... of them have something else in common: They have ... Gluten Free Therapeutics, makers of CeliVites nutritional ... by publishing a series of blog posts aimed at ...
(Date:10/1/2014)... Anti Aging Clinic (AntiAgingClinic.ca), the Greater Toronto ... choice, is announcing a discounted cost on Botox units, ... “We’re doing this because we want to give as ... clinic in Toronto,” says Dr. Brian Sieber, founder of ... Aging Clinic, including laser facials, genesis laser facials, ...
(Date:10/1/2014)... 2014 Nordic Naturals is kicking ... special cause. The campaign—“Buy One Bottle. Help Two ... Veterans, a nonprofit organization that helps rebuild the ... dogs that would otherwise face euthanasia. From October ... support monthly donations of Nordic Naturals omega-3s to ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
... men with prostate cancer were more likely to report ... among siblings than men who did not have prostate// ... Comprehensive Cancer Center. ,The data were part of ... African-American men ages 40-79 who live in Flint, Mich. ...
... sex and transfusion of HIV-infected blood could push Madhya Pradesh ... experts. // ,The number of AIDS-affected people in ... in 1988 to 1,933 till October 2006. ... unprotected sex, 23 percent were caused by transfusion of infected ...
... to have his hand transplanted successfully at US by a ... consisted of doctors from Jewish hospital, the University of Louisville, ... Center who conducted a long surgery from 3.10 pm on ... is David F. Savage, 54, of Bay City in Mich. ...
... urged Parliamentarians to see that a robust and effective ... their day-to-day life is brought into force within the ... on World AIDS Day organized by Parliamentarians Forum on ... made the following suggestions to MPs, research laboratories, the ...
... girl may well be the clue to how it grasps and ... of its kind.// ,A discovery from two Georgetown neuroscientists put ... While female brains tend to assimilate language using words and the ... the language. This may well explain mistakes like “I holded the ...
... to a study women talk three times men do, where an ... woman can talk up to 20,000 words. No wonder it is// ... house not talking much. ,Dr. Luan Brizendine, psychiatrist at University ... an eminent feminist claims that women tend to devote more brain ...
Cached Medicine News:Health News:African-Americans With Prostate Cancer More Likely to Have Family History 2Health News:Unsafe Sex, HIV Infected Transfusion Spreading AIDS in Madhya Pradesh 2Health News:President Urges to Avoid Discrimination Against AIDS Patients 2Health News:Gender Might Have a Say in How Your Child Speaks 2Health News:Gender Might Have a Say in How Your Child Speaks 3